Recombinant Human CTACK/CCL27 #abs01146

abs01146-5ug

1-2 Weeks

138

abs01146-20ug

1-2 Weeks

344

abs01146-1mg

1-2 Weeks

3891

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm and then lyophilized to produce a dry powder. To ensure purity, measures were taken to create a highly filtered and concentrated product. The resulting lyophilized substance is ideal for long-term storage and transportation, as well as for various research applications. The original solution's pH was carefully monitored to ensure a stable and consistent pH value throughout the process. Overall, the final lyophilized product represents a reliable source of purified substance with a wide range of potential uses in the scientific community.

Properties

aa_sequence

QALRCVFLHQ LKWGQPMFKD LGRMLKFVIR QADCEGDLHL LFAHQRVILS CPPQIHPSNI LREKJPFTSW HLEQFKPGRW GMNLRFKKL.

Concentration

> 96 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The Recombinant HumanCTACK/CCL27 has been determined to have a very low endotoxin level of less than 0.1 EU/μg, as confirmed by the LAL method. To create a similar but distinct content, one could restate the information as follows: The LAL method found that the Recombinant HumanCTACK/CCL27 exhibits an extremely low endotoxin level of less than 0.1 EU/μg, indicating its high purity and quality.

Activity

The biological potency of this substance matches that of the standard, as determined by a chemotaxis bioassay using BaF3 cells transfected with CCR10. The concentration required to elicit biological activity falls within the range of 10-100 ng/ml.

Reconstitution

To ensure optimal use, it is recommended that the vial is briefly centrifuged before opening to allow the contents to settle at the bottom. The reconstitution process involves adding sterile distilled water or an aqueous buffer that contains 0.1% BSA to achieve a concentration range of 0.1-1.0 mg/mL. It is advisable to prepare stock solutions and divide them into working aliquots, which can be stored at temperatures of ≤ -20 °C for future use. Any further dilutions should be carried out in appropriately buffered solutions for best results.

Stability & Storage

To ensure the stability of this lyophilized preparation, it is recommended to store it at 2-8°C. However, for long-term storage, it should be kept at -20°C, and preferably in a desiccated state. Upon reconstitution, the preparation can be stored for up to one week at 2-8°C. For optimal stability, it is advised to divide the reconstituted preparation into working aliquots and store them at temperatures between -20°C to -70°C. Avoid exposing the preparation to repeated freeze/thaw cycles, as this may affect its quality.

Target

Accession

Q9Y4X3

Gene IDs

10850